Genetic determinants of warfarin dosing in the Han-Chinese population. - Wikidata - wikimedia - TriplyDB

Genetic determinants of warfarin dosing in the Han-Chinese population.

Genetic determinants of warfarin dosing in the Han-Chinese population.

http://www.wikidata.org/entity/Q43230870

about

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups Warfarin Pharmacogenetics: New Life for an Old Drug Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome Pharmacogenetics of warfarin: challenges and opportunities.Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses Warfarin dosage response related pharmacogenetics in Chinese population.Genetic warfarin dosing: tables versus algorithms.Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis Role of pharmacogenomics in the management of traditional and novel oral anticoagulants Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis Association of genetic polymorphisms with warfarin dose requirements in Chinese patients.Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement The pharmacogenetics of the response to warfarin in Chinese.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population.Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis.Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.Replication study of CYP4F2 association with warfarin response in an Israeli population.Prothrombotic SERPINC1 gene polymorphism may affect heparin sensitivity among different ethnicities of Chinese patients receiving heart surgery.Effect of gene polymorphims on the warfarin treatment at initial stage.Gamma-glutamyl carboxylase and its influence on warfarin dose.Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement

P2860

Q28071310-21F8D5E1-BCD2-484A-BA54-1AAB2922BC7D Q28083875-94AA6FE8-FCD2-4893-B185-FE9B423FEDF1 Q28276514-12BB9BD8-2D9D-448C-A884-7B14C4B4425C Q28395337-64078AC4-70E7-4B88-9812-10F4C8DEB0DB Q28468726-0B085C55-3EC7-499F-B08F-F8433574A57F Q31016306-2DD26AF8-228F-4397-BF35-A61F26A86C7F Q33760056-7BFC6C56-C004-4FC0-AFAD-6085A245ADA5 Q33819050-EFAEE64C-C9D5-4EB8-A8E3-520B98092967 Q34078825-A636CE9E-C507-403B-B120-41DFCDF767B5 Q34977531-6CBED7EC-8FDB-4655-9C38-C87A2EAEC5E5 Q35021027-C205DD0D-635B-45A7-B3D0-2614B2111901 Q35795269-7716FFF6-1E91-4A5D-B1DE-020B8A766930 Q36368040-2C71B096-8519-4819-846C-426DBA5B76F6 Q36742224-143481FC-F414-4D50-9AC0-C4EB3AD0293E Q36848449-737EEEC2-4994-4B49-A791-489663317FC6 Q37065161-E6984EF1-AF2E-459A-8FF4-70E8ABCC11AD Q37398193-43F94915-851A-4D14-BD0A-6037437AE6C2 Q37398898-7A780A4D-F8CB-413F-9927-0F275A563B8D Q37606335-5DF9203B-A795-45C8-867F-27E6CFB51BD2 Q37948863-A24E49B2-6386-49B7-A02F-E7169EFF3FA5 Q38078754-AF243090-4D65-47B5-8B4C-7BE50742F84B Q38760559-247BF9B5-4185-4D20-888B-4E3F664ECB23 Q38897904-370577BE-B459-409F-A55B-787C8F3A15FB Q39096673-E99000C0-80B1-4BD7-9832-48293C4CEB54 Q39471514-BE4C6662-489E-4F3E-B2DF-1E27524912EF Q39537454-FC43D100-F56F-407B-B348-5435EF700310 Q41824237-993926BB-86BE-41E0-B956-0703C0BB6BE9 Q42713959-CCEAE94B-F168-4A75-B055-6B077FFC0FEF Q42718669-AD2C73A8-5576-46EA-B21F-3C29CCD8E96B Q42722817-5A0CE935-E77D-4950-9806-557C2D03ACB0 Q42791847-DD002676-08E6-4532-A558-345D1935CAEB Q42910090-DE10E65D-8C42-46A2-8350-3948EE9B056A Q44498037-E84EA6AB-D943-446F-B36C-081F12D310AB Q44865332-5B16E76F-2327-43B4-844A-BDA4AD0EB48A Q47834832-9BC84160-3C8D-4A42-9E07-CA2CF0C2D84E Q48905886-A2E6DE9D-4264-4AD3-B4BC-7DD92DD15CFD Q49811574-373974F1-F2F8-4A11-B4B3-41FCF6A72FCF Q53123110-513E1AD6-1A38-47D3-BCCF-372A593A8A27 Q53268012-337B70A7-FE38-4939-97ED-C5CF18608279 Q57500191-D875A486-4E8C-4F4A-B7A7-1E4E2C8C8517

P2860

Genetic determinants of warfarin dosing in the Han-Chinese population.

http://www.wikidata.org/entity/Q43230870

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Genetic determinants of warfarin dosing in the Han-Chinese population.

@en

Genetic determinants of warfarin dosing in the Han-Chinese population.

@nl

type

label

Genetic determinants of warfarin dosing in the Han-Chinese population.

@en

Genetic determinants of warfarin dosing in the Han-Chinese population.

@nl

prefLabel

Genetic determinants of warfarin dosing in the Han-Chinese population.

@en

Genetic determinants of warfarin dosing in the Han-Chinese population.

@nl

P1433

Q43230870-F7EB62E0-FB96-4A44-BC70-26675E85B33F

P1476

Q43230870-40138E42-A0D8-496B-B3C1-68525917758E

P2093

Q43230870-1922279C-8FF5-4148-AFDC-6E380787FFD2

Q43230870-45D3CD23-631E-4C74-8988-1E0B5A997587

Q43230870-55312CBA-191E-4B50-9007-B091713749C0

Q43230870-5935DC0A-6E49-4DFE-B697-3F296FE205E8

Q43230870-768CD48A-1ED7-4FDF-9047-45B2A2234CB1

Q43230870-8212DBA2-1FEA-4CC8-B739-762BF3F8C6F7

Q43230870-CAAD7B19-3CFD-4193-B316-730B7B27BE3A

Q43230870-D490181B-AC42-41DA-83D9-E426EF2C6EB7

Q43230870-DBF66495-4CE3-4874-87B2-505AD51A62DF

Q43230870-E29EA6EA-BEA5-4AFC-BC4E-85C35E1C5F75

P2860

Q43230870-0689F7EE-9264-408E-A8AC-AAEBC986DD24

Q43230870-0755F823-BB09-413C-B9B6-F9732388F04F

Q43230870-0D14503C-10EE-4358-920B-3A496DCE4120

Q43230870-0E7C70DA-E879-4EAD-8919-8DF5FC7B4AF0

Q43230870-1236CB70-ED22-414D-8985-79FCDB5F206B

Q43230870-1DD207AE-5FF9-4A97-95BE-9951870DDA3B

Q43230870-3270E9FB-2B8A-4212-A4A1-68F913539716

Q43230870-35F93358-B214-4028-9E75-1A324000FCDE

Q43230870-3E7FAEEF-025B-4612-BA8C-C826922630F0

Q43230870-44695F73-5034-4256-AC78-4CD0F8BDD0DD

P304

Q43230870-19B299F8-E132-4350-B4CF-7DA8FEFF72B3

P31

Q43230870-48DE475A-DE93-4E48-9A17-C67C271CA08D

P356

Q43230870-7B7874B1-6EF4-4600-8B1E-C9917E53BCFD

P433

Q43230870-FED17847-93E0-4681-A3BD-603470E31D20

P478

Q43230870-F1998860-2E28-4D16-B37B-3817682ECB30

P50

Q43230870-E0C02A96-3B11-494F-AC75-F5431F34ACFD

P577

Q43230870-0FA6B0DF-5558-4FBD-A196-D30669CFEB2E

P698

Q43230870-E60CE4F3-44BC-4E4C-B509-37ADF855890A

P356

P1433

Pharmacogenomics

P1476

Genetic determinants of warfarin dosing in the Han-Chinese population.

@en

P2093

Amir N Saleem

http://www.w3.org/2001/XMLSchema#string

Chien-Hsiun Chen

http://www.w3.org/2001/XMLSchema#string

Ching-Heng Chou

http://www.w3.org/2001/XMLSchema#string

Hui-Ping Chuang

http://www.w3.org/2001/XMLSchema#string

Jer-Yuarn Wu

http://www.w3.org/2001/XMLSchema#string

Jin-Jer Chen

http://www.w3.org/2001/XMLSchema#string

Liang-Suei Lu

http://www.w3.org/2001/XMLSchema#string

M T Michael Lee

http://www.w3.org/2001/XMLSchema#string

Ming-Shien Wen

http://www.w3.org/2001/XMLSchema#string

Ying-Ting Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

CYP2C9 allelic variants: ethnic distribution and functional significance

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Pharmacogenetics of warfarin elimination and its clinical implications.

The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

P304

1905-1913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.09.106

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Yuan-Tsong Chen

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19958090

http://www.w3.org/2001/XMLSchema#string